Phenylboronic-acid-modified nanoparticles: potential antiviral therapeutics M Khanal, T Vausselin, A Barras, O Bande, K Turcheniuk, M Benazza, ... ACS applied materials & interfaces 5 (23), 12488-12498, 2013 | 73 | 2013 |
Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response C Miroux, T Vausselin, N Delhem Expert opinion on biological therapy 10 (11), 1563-1572, 2010 | 69 | 2010 |
High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication. BCF Edwards MR, Pietzsch C, Vausselin T, Shaw ML, Bukreyev A ACS Infect Dis 1 (8), 380-387, 2015 | 59 | 2015 |
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus T Vausselin, K Séron, M Lavie, AA Mesalam, M Lemasson, S Belouzard, ... Journal of virology 90 (19), 8422-8434, 2016 | 48 | 2016 |
The antimalarial ferroquine is an inhibitor of hepatitis C virus T Vausselin, N Calland, S Belouzard, V Descamps, F Douam, F Helle, ... Hepatology 58 (1), 86-97, 2013 | 46 | 2013 |
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry M Khanal, A Barras, T Vausselin, L Fénéant, R Boukherroub, ... Nanoscale 7 (4), 1392-1402, 2015 | 28 | 2015 |
New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore monensin A L Fénéant, J Potel, C François, F Sané, F Douam, S Belouzard, N Calland, ... Journal of virology 89 (16), 8346-8364, 2015 | 21 | 2015 |
SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses D Dornfeld, AH Dudek, T Vausselin, SC Günther, JF Hultquist, S Giese, ... Scientific reports 8 (1), 2092, 2018 | 18 | 2018 |
Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice S Belouzard, A Machelart, V Sencio, T Vausselin, E Hoffmann, ... PLoS Pathogens 18 (5), e1010498, 2022 | 12 | 2022 |
Safety and efficacy of avaren-Fc lectibody targeting HCV high-mannose glycans in a human liver chimeric mouse model M Dent, K Hamorsky, T Vausselin, J Dubuisson, Y Miyata, Y Morikawa, ... Cellular and molecular gastroenterology and hepatology 11 (1), 185-198, 2021 | 10 | 2021 |
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro L Fénéant, J Ghosn, B Fouquet, F Helle, S Belouzard, T Vausselin, ... PloS one 10 (11), e0142539, 2015 | 10 | 2015 |
An Arginine-Rich Motif in the ORF2 capsid protein regulates the hepatitis E virus lifecycle and interactions with the host cell K Hervouet, M Ferrié, M Ankavay, C Montpellier, C Camuzet, V Alexandre, ... PLoS Pathogens 18 (8), e1010798, 2022 | 7 | 2022 |
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology S Belouzard, A Machelart, V Sencio, T Vausselin, E Hoffmann, ... | 3 | 2021 |
The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif K Hervouet, M Ferrié, M Ankavay, C Montpellier, C Camuzet, V Alexandre, ... | 3 | 2021 |
A DNA vaccine expressing fusion protein E2-NT (gp96) induces hepatitis C virus cross-neutralizing antibody in BALB/c mice E Kord, J Dubuisson, T Vausselin, AA Amirzargar, MS Yekaninejad, ... Hepatitis Monthly 19 (9), 2019 | 1 | 2019 |
BacMam virus-based surface display for HCV E2 glycoprotein induces strong cross-neutralizing antibodies and cellular immune responses in vaccinated mice E Kord, F Roohvand, J Dubuisson, T Vausselin, H Nasr Azadani, ... Infectious Agents and Cancer 16, 1-12, 2021 | | 2021 |
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology (preprint) S Belouzard, A Machelart, V Sencio, T Vausselin, E Hoffmann, ... | | 2021 |
Composés pour la prévention ou le traitement des infections par des virus de la famille des Flaviviridae GY Vausselin T, Dubuisson J, Biot C, Wychowski C WO Patent 2013156957 A1, 2013 | | 2013 |